Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | BRD2 | P25440 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18174254 | 0.91 | ERN1 (0.49) | ERN1BRD4GAABRD2CREBBP | |
| SCHEMBL18174242 | 0.86 | BRD4 (0.51) | ERN1BRD4GAABRD2CREBBP | |
| SCHEMBL20094321 | 0.83 | MAPT (0.52) | ERN1BRD4GAABRD2CREBBP | |
| SCHEMBL29741428 | 0.83 | MAPT (0.52) | ERN1BRD4GAABRD2CREBBP | |
| SCHEMBL18181936 | 0.83 | LMNA (0.49) | ERN1BRD4GAATP53POLB | |
| SCHEMBL20094295 | 0.83 | ERN1 (0.47) | ERN1BRD4GAABRD2TP53 | |
| SCHEMBL29741304 | 0.83 | ERN1 (0.47) | ERN1BRD4GAABRD2TP53 | |
| SCHEMBL31410098 | 0.82 | ERN1 (0.47) | ERN1BRD4GAABRD2TP53 | |
| SCHEMBL18174218 | 0.82 | ERN1 (0.41) | ERN1BRD4GAABRD2TP53 | |
| SCHEMBL20061675 | 0.81 | ERN1 (0.48) | ERN1BRD4BRD2CREBBPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | EP300, HDAC3, HDAC1 | ERN1 1781/4885BRD4 18/4885GAA 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.